BXRX

Baudax Bio, Inc.

0.18 USD
+0.16 (+699.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Baudax Bio, Inc. stock is up 512.67% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 February’s closed higher than January.

About Baudax Bio, Inc.

Baudax Bio, Inc. develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB)